ALT-GIST: A randomized phase II trial of Imatinib ALTernating with Regorafenib compared to Imatinib alone for first line treatment of advanced gastrointestinal stromal tumour (GIST)

ANITA: A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor Nintedanib with the intravenous cytotoxic compound Ifosfamide for treatment of patients with advanced, metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based firstline chemotherapy for inoperable disease 

ANNOUNCE 2: A phase Ib (open label)/phase II (only) randomized, double-blinded study evaluating the efficacy of Gemcitabine and Docetaxel with or without a human anti-PDGFRa monoclonal antibody (Olaratumab) in the treatment of advanced soft tissue sarcoma (Academic)

Bone Sarcoma CTC study: Optimisation of circulating tumour cell detection in bone sarcomas

CaboGIST EORTC 1317: Phase II study of Cabozantinib in patients with metastatic gastrointestinal stromal tumour (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with Imatinib and Suntinib

CASPS: A phase II trial of Cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS). This trial is testing a new drug Cediranib that has already shown promising results in a small number of patients with alveolar soft part sarcoma. Cedirinib works by inhibiting growth of blood vessels in tumours.

CREATE: a cross-tumoral phase II trial exploring Crizotinub (PF-02341066) in patients with advanced tumours induced by casual alterations of ALK and/or MET

EE 2012: an international randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours

EZH202: A phase II, multicentre study of the EZH202 inhibitor Tazemetostat in adult subjects with INI1-negative tumours or relapsed refractory synovial and epitheliod type

GOG-0277: A phase III randomised trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcoma

HOPE: Phase I/II study of Lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma

Paragon: a phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms

RMS 2005: A protocol for non-metastatic rhabdomyosarcoma. This study is investigating the use of chemotherapy in the treatment of children and teenagers with rhabdomyosaroma that has not spread around the body

VIT 0910: International randomized phase II trial of the combination of Vincristine and Ironotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdosarcoma